The Keynote 942 study didn't just show clinical improvement; it demonstrated that the neoantigen vaccine expanded specific T-cell clones associated with positive patient response. This confirms the therapy's intended biological mechanism of action, a critical step for validating this new class of cancer treatment.
Despite its small size and inability to immediately change clinical practice, the Keynote 942 trial's strength was in generating a powerful, unambiguous signal of efficacy. This approach proved highly effective at catalyzing broader interest and investment in personalized neoantigen vaccines across the entire field of oncology.
The rapid adoption of neoadjuvant immunotherapy as the superior standard of care means this new adjuvant vaccine faces an uphill battle for relevance. Its true future impact hinges on proving its efficacy when combined with neoadjuvant therapy, a combination that could potentially lead to unprecedentedly low relapse rates for patients.